The University Hospital of Zürich (German: Universitätsspital Zürich, USZ) is one of five university hospitals in Switzerland.The first hospital in Zürich, from which the current hospital derives, is recorded as having existed as early as 1204. The name, location and buildings have since changed many times. As of 2008[update], the hospital employs an approximate staff of 8,000 (1,200 doctors, 2,400 care professionals, 980 medical-technical and medical-therapeutic specialists) providing medical care to 134,000 ambulant and over 35,000 stationary patients each year in 42 clinics.Scientists and physicians of international renown who have practiced at the hospital include Ferdinand Sauerbruch, Andreas Grüntzig and Rolf M. Zinkernagel; the latter received a Nobel Prize for research done at the hospital..
Purpose Replacement of the distal radioulnar joint (DRUJ) using a semiconstrained implant arthroplasty (Aptis) has demonstrated the capacity to restore function. The aim of this study was to investigate medium-term outcomes and navigate the effect of increasing experience with this implant, and compare the results with other follow-up studies. Methods We retrospectively investigated 36 DRUJ implant arthroplasties in 34 patients operated on between 2010 and 2021 for complications and revision surgeries. The average follow-up time was 4.4 years. In 15 patients with available data and surviving implant over time, we compared pre- and postoperative pain level and total active motion, as well as weight-bearing ability. Results Overall pain reduction was significant. Active range of motion and weight bearing ability was stable over time. We observed no infection. Revision surgery was necessary in 27% of cases, and the overall survival rate of the implant was 91% with a mean follow-up of 53 months. Conclusion We conclude that implant arthroplasty of the DRUJ reduces pain and preserves function. An extremely precise surgical technique is mandatory to avoid complications. Type of study/level of evidence Prognosis/IIb.
Distal radius fractures (DRFs) account for 15% of all fractures in adults. Optimal treatment of DRFs depend on patient and fracture characteristics. Non- or minimally displaced DRFs can be treated nonoperatively with a cast. Although surgical treatment is becoming more popular, the majority of patients with a DRF are still treated nonoperatively. In addition, these considerations may be different for elderly patients. Conflicting evidence exists on the different aspects of treatment of DRFs. These recommendations regarding distal radius fractures describe considerations regarding diagnostic modalities, associated soft tissue injuries, different treatment options, rehabilitation protocol, considerations for treatment of elderly patients, follow-up decisions and possible complications. The aim is to aid the orthopedic traumasurgeon in decision making and treatment of distal radius fractures.
Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease characterized by progressive joint involvement. The disease is associated with reduced health-related quality of life, functional ability, work productivity, and daily activity, in addition to pain, fatigue, and inflammation-induced structural damage. RA emerges through a complex interplay of multiple factors, including the release of inflammatory cytokines. One such cytokine is tumor necrosis factor (TNF), which is inhibited by golimumab, an approved treatment for the disease. Golimumab is produced using a recombinant cell line that originated from genetically modified mice immunized with human TNF. This narrative review presents the efficacy and safety outcomes from the golimumab pivotal randomized controlled trials (RCTs) that evaluated the subcutaneous and intravenous formulations. Across the RCTs, treatment was associated with an American College of Rheumatology ≥ 20
Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder caused by germline inactivation of the folliculin gene (FLCN). Approximately 25
The study investigated the effectiveness of dysgeusia-specific acupuncture combined with self-acupressure compared to supportive acupuncture and self-acupressure for chemotherapy-induced dysgeusia in cancer patients with cancer-related fatigue (CRF) and dysgeusia. This multicenter, randomized, controlled, two-armed parallel-group, single-blind trial included cancer patients with CRF and dysgeusia during chemotherapy. All participants received CRF treatment consisting of eight acupuncture sessions over 8 weeks and had access to an eLearning course for self-acupressure. Patients in the intervention group received additional dysgeusia-specific acupuncture treatment and an eLearning with instructions to acupressure points, whereas the control group received an intervention focused solely on addressing CRF. The main outcome was perceived dysgeusia over 8 weeks, measured weekly after each acupuncture session on a numeric rating scale from 1 to 10. Other outcomes included taste and smell tests, and assessments of perceived dysgeusia, fatigue, distress, and quality of life. Due to a small sample size, results can be only judged exploratory. The study was approved by the Cantonal Ethics Committee (CEC) (Kanton Zürich Kantonale Ethikkommission) (approval no. KEK-ZH-Nr. 2020—01900). Since we included only twenty-one patients (11 intervention, 10 control, 90
